Company: PSTV
Filing Date: 2025-07-11
Form Type: PRE 14A
Source: 0001140361-25-025650
Chunk: 1

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-07-11
Form: PRE 14A
Chunk 1
---
 on our successful Phase 1 adult glioblastoma trial. The results of the trial show substantial safety margins, signs of efficacy and was published earlier in 2025 in the prestigious medical journal Nature Communications. Our glioblastoma Phase 2 trial, ReSPECT-GBM, continues to enroll patients in 2025. Each of these trials continues to benefit from approximately $25M in active grant support. Since the acquisition of CNSide, we have laid the ground work for a successful relaunch of CNSide here in the US. Those preparatory activities are largely complete and we plan to reintroduce the product in Texas in the second half of 2025 and extend that launch to all 50 states. Furthermore, in the past year, we have published a number of scientific articles showing clinical value of CNSide, its core test now recemented in the National Comprehensive Cancer Center Guidelines, completed and presented the FORSEE clinical trial results clearly showing its clinical value, built out a centralized testing laboratory in Houston, validated key commercial elements such as pricing and reimbursement and hired an experienced diagnostics executive team to lead the CNSide commercial subsidiary. Our conviction is higher than ever that CNSide uniquely fills a $6B hole in the CNS cancer diagnostic space. Finally, we have taken a number of actions to capitalize the company beyond our existing grant funding that will help bridge our capital requirements from our current position to diagnostic revenue and ultimately to FDA approval of REYOBIQ. The past year for Plus has been noteworthy for material clinical progress and a game-changing acquisition that was both opportunistic and strategic that we think will soon reward our stockholders. On behalf of our employees, management and directors, I would like to express our deep appreciation to our stockholders and partners for their help and support in 2024 and beyond.

| Sincerely,                          |
| Marc H. Hedrick, M.D.               |
| President & Chief Executive Officer |

TABLE OF CONTENTS

NOTICE OF 2025 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON AUGUST 7, 2025

| PLUS THERAPEUTICS, INC.    
 Headquarters               
 2710 REED ROAD, SUITE 160, 
 HOUSTON, TX 77002          |     | MEETING LOCATION:                          
 www.virtualshareholdermeeting.com/PSTV2025 |

Dear Plus Therapeutics, Inc. Stockholder: You are cordially invited to attend the 2025 Annual Meeting of the Stockholders of Plus Ther